Drugs / Human Rabies Immunoglobulin
Trials 0
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02559921 Comparator | Dec 2014 → Aug 2015 | rabies | Beijing Chaoyang District Centre for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05846568 Comparator | Oct 2022 → Sep 2023 | rabies | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02177032 Comparator | Jun → Oct 2014 | rabies | Novartis | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Rabies Immunoglobulin | “In this study, a population pharmacodynamic (PPD) model was established to compare the neutralizing antibody activities of Ormutivimab and human rabies immunoglobulin (HRIG),...” PMID 36016106 ↗ Jul 2022 |
| Known as | HRIG | “In this study, a population pharmacodynamic (PPD) model was established to compare the neutralizing antibody activities of Ormutivimab and human rabies immunoglobulin (HRIG),...” PMID 36016106 ↗ Jul 20221“The HRIG is a Chinese licensed Human Rabies Immunoglobulin produced by BOYA-BIO, which are derived from human plasma, and then purified and filled in the injectable vial form.” NCT05846568 ↗ |
| Modality | Protein / enzyme biologic | “Rabies immunoglobulins” NCT02177032 ↗ |
| Route | Intramuscular | “20 IU/kg body weight intramuscularly” NCT02177032 ↗ |